Objective: To determine actual first-line treatment patterns for metastatic triple-negative breast cancer (mTNBC) in the United States by analyzing records of patients treated in community practices.
Methods: We derived our data from the Georgia Cancer Specialist Database (GCSD) (2003-2008) and the International Oncology Network’s (ION) Treatment and Outcomes Database (2003-2008). In both data sets, patients with stage IV TNBC were selected and followed for up to 1 year after the initial mTNBC diagnosis. Chemotherapy was deemed first-line if initiated within 120 days of mTNBC diagnosis.
|Title||Expiration Date||CME Credits|
|Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?||Jul 31, 2019||1.5|
|Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid Foundation||Aug 15, 2019||1.5|